Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	322M 281M 260M 244M 457M 30.42B 460M 3.09B 1.2B 14.97B 1.21B 1.18B 51.99B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	418M 365M 338M 316M 593M 39.49B 597M 4.01B 1.55B 19.44B 1.57B 1.54B 67.49B	EV / Sales 2026 *	-	EV / Sales 2027 *	11.5x
Free-Float	95.04%	Yield 2026 *	-	Yield 2027 *	-

05-16	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
04-16	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-15	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
11-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-14	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
31/10/25	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
27/10/25	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI
24/10/25	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.	CI
27/08/25	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.	CI
18/08/25	Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman	CI
15/08/25	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
30/06/25	Northwest Biotherapeutics, Inc. announced that it expects to receive $2.85 million in funding from Yorkville Advisors Global LP	CI

05-16	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ
04-30	Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform	PR
04-21	Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic	PR
11-20	Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility	PR
11-15	Northwest Biotherapeutics: Q3 Earnings Snapshot	AQ

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	01/06/2007
Linda Powers CEO	Chief Executive Officer	71	08/06/2011
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	01/01/2000

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	01/01/1998
Linda Powers CHM	Chairman	71	17/05/2007
Navid Malik BRD	Director/Board Member	57	01/04/2012

Northwest Biotherapeutics, Inc Stock Nasdaq

Stocks

US66737P6007

Biotechnology & Medical Research

Valuation: Northwest Biotherapeutics, Inc

Latest news : Northwest Biotherapeutics, Inc

Press Releases: Northwest Biotherapeutics, Inc

Quotes and Performance

Managers and Directors: Northwest Biotherapeutics, Inc

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NORTHWEST BIOTHERAPEUTICS, INC	+3.38%	+19.13%	-	-	322M
ARGENX SE	+1.44%	-1.25%	+64.25%	+116.08%	55.19B
WUXI APPTEC CO., LTD.	+4.60%	+3.02%	+57.38%	+62.27%	45.75B
BIONTECH SE	-1.44%	+0.39%	-14.68%	-15.42%	22.98B
INSMED INCORPORATED	-2.69%	-2.10%	-6.70%	+363.03%	20.76B
WUXI BIOLOGICS (CAYMAN) INC.	-1.36%	-1.68%	+24.08%	-19.47%	16.26B
GENMAB A/S	+0.58%	+1.08%	+18.85%	-36.52%	15.42B
EXELIXIS, INC.	-1.01%	-2.30%	+28.59%	+173.07%	13.05B
PHARMAESSENTIA CORPORATION	+4.95%	+11.70%	+125.78%	+261.94%	12.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-5.77%	-6.54%	+19.60%	-	12.37B
Average	+0.27%	+2.28%	+35.24%	+113.12%	23.8B
Weighted average by Cap.	+0.77%	+1.51%	+39.95%	+104.42%

	2026 *	2027 *
Net sales	-	38.93M 33.95M 31.44M 29.43M 55.2M 3.67B 55.53M 373M 145M 1.81B 146M 143M 6.28B
Net income	-	-
Net Debt	96.08M 83.77M 77.59M 72.63M 136M 9.07B 137M 920M 357M 4.46B 361M 353M 15.49B	125M 109M 101M 94.44M 177M 11.79B 178M 1.2B 464M 5.8B 469M 459M 20.15B